Objective: To evaluate the efficacy, safety, and cost-effectiveness of proprotein convertase
subtilisin-kexin type 9 (PCSK9) inhibitors and describe its place in therapy for the treatment …

Objective: Unusual or unexpected effect of treatment Background: Real-life data on the
efficacy of monotherapy with PCSK9 inhibitors are scarce. Most cohort studies have …

Background To date, little information is available on the real impact of PCSK9 inhibitors in
terms of reducing cholesterolemia, events and the actual tolerability in the so-called “real …

Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and
dyslipidemia is one of the major risk factors. Hypercholesterolemia is the most common form …

Purpose Evolocumab, a monoclonal inhibitor of proprotein convertase subtilisin/kexin 9, has
been shown to reduce proatherogenic lipoproteins in patients with or without familial …

Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density
lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains …

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have emerged as a novel
treatment option in patients with hypercholesterolemia. Evolocumab and alirocumab have …

The proof of concept that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
affects cholesterol levels was first established after the demonstration that PCSK9 loss-of …

Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce low-
density lipoprotein cholesterol (LDL-C) levels and are approved for patients with familial …

Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic …